bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

hooksAmpRedirectArticle

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

paywallTypes

createdDate

publishedDate

sponsorType

urlAlias

moreOnThisArticles

commentCount

authorLocations

authors

corrections

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

articleSpeeches

socialHeadline

headline

images

flag

firstTopic

glossary

flattenTypeIds

image

relatedLinks

relatedNewsletters

__typename

sponsor

pdfFiles

seriesReverseOrder

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

readingTime

customTimezone

liveContents

Holly Chik

At least a fifth of the world’s population will not have access to Covid-19 vaccines until 2022, according to a new analysis.
The study of pre-approval orders placed for drugs found that high-income countries, which comprise 14 per cent of the world’s population, have reserved half the 7.5 billion does from 13 leading vaccine developers.
The team from Johns Hopkins Bloomberg School of Public Health in the US found that low and middle income countries had placed orders with six manufacturers although they represent a much greater share of the world’s population.
The world is racing to produce safe and effective vaccines against the coronavirus which has infected more than 75 million people and killed 1.7 million.
US authorises second Covid-19 vaccine amid winter surge
Britain and the United States have started to inoculate their people, while European Union countries will roll out jabs from late December.
But the timeline could be unclear in other countries. “Even if all 13 of these vaccine manufacturers were to succeed in reaching their maximum production capacity, at least a fifth of the world’s population [over 1.5 billion people] would not have access to vaccines until 2022,” the researchers wrote.
The United States, the country worst-hit by Covid-19 with a fifth of all cases globally, has reserved 800 million doses. Japan, Australia, and Canada have pre-ordered more than one billion doses in total, although they only account for nearly 1 per cent of global Covid-19 cases.


The research was published in The BMJ, the journal of the British Medical Association, on Tuesday, days before Covax, the global initiative for fair distribution of Covid-19 vaccines, announced that it has secured almost 2 billion doses of several “promising” vaccine candidates.
The 190 participating countries will have “access to doses in the first half of 2021, with first deliveries anticipated to begin in the first quarter of 2021,” according to the World Health Organization.
The scheme has already signed up vaccine developers including AstraZeneca and Johnson & Johnson, as well as the world’s largest manufacturer of vaccines by volume, the Serum Institute of India. Talks are continuing with other drug firms, including Moderna and Pfizer-BioNTech.
The study also shed light on nations’ strategy to diversify their vaccine portfolio. The US, Britain, European Union and Canada have placed orders with at least six different manufacturers, Japan with at least four, and Brazil with at least three.
Vaccines for world’s vulnerable no guarantee of a ‘silver bullet’: WHO
Price and the temperature at which the vaccines must be stored are also a consideration. More than 40 per cent of pre-market commitments from high-income countries involved the vaccine developed by Oxford University and AstraZeneca, which can be kept in a fridge and is the cheapest available.
The UK-made vaccine costs US$8 per course for countries such as the US, Britain, Brazil and China, and US$6 per course for doses produced by the Serum Institute of India, which are destined for low and middle-income countries.
Only wealthy nations have been able to procure vaccines from Pfizer-BioNTech and Moderna, both of which have been approved by the US for emergency use.


The vaccines use advanced genetic techniques and have an efficacy rate of over 90 per cent, but they are much more expensive than the Oxford drug and need to be stored in ultracold temperatures.
The BioNTech-Pfizer vaccine is priced at US$39 per course and Moderna’s at US$64 to US$74 per course.


Scientists test universal vaccine for cold, flu, Covid and allergies

The hidden benefits of common vaccines, including reduced dementia and heart risks

Judge allows lawsuit against RFK Jnr’s Covid-19 vaccine policies to proceed

US vaccine advisers say not all newborns need hepatitis B shot, in win for RFK Jnr

Coronavirus vaccine

A fifth of the world’s population may have to wait more than a year to get Covid-19 vaccine

A Florida nurses receives the Pfizer-BioNTech vaccine after US regulators approved the use of the drug. Photo: AP

Coronavirus: Cambodia ‘not shunning’ China vaccines

Cambodia's Prime Minister Hun Sen says his country will only take coronavirus vaccines approved by the World Health Organization. Photo: AP

Coronavirus: US President-elect Joe Biden in line for vaccine on Monday as US leaders start receiving injections

Top US infectious disease expert Anthony Fauci has urged President-elect Joe Biden, along with President Donald Trump, to get vaccinated as quickly as possible for security reasons. Photo: dpa

U.S. Vice President Mike Pence receives the COVID-19 vaccine at the White House in Washington, U.S., December 18, 2020. REUTERS/Cheriss May TPX IMAGES OF THE DAY

U.S. President Donald Trump pauses while speaking during a news conference at the White House on September 4, 2020 in Washington, D.C. (Drew Angerer/Getty Images/TNS)

Coronavirus: China set for 100 million doses of BioNTech vaccine amid roll-out of shots overseas

A nurse prepares to administer the Pfizer-BioNTech COVID-19 vaccine at Guy's Hospital in London, Britain, on December 8, 2020. Photo: Reuters

News

China

Science

Coronavirus

Health & Medicine


Study finds that richer countries account for more than half the reservations placed with drug companies
Researchers conclude than more than 1.5bn people will not get access to the drugs next year



Study finds that richer countries account for more than half the reservations placed with drug companies.
